Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga ® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancer (for specialized target groups only)

Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trial
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news